You are here: Industry Insights > Daewoong

News List

Camostat cuts recovery time in half for mild COVID-19 patients europeanpharmaceuticalreview
August 02, 2021
Phase II trial results suggest Daewoong Pharmaceutical’s Foistar (Camostat mesilate) may significantly expedite recovery from mild COVID-19 symptoms.
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial prnasia
July 29, 2021
Daewoong Pharmaceutical (CEO Sengho Jeon) announced its phase 2B clinical trial topline results for Foistar (Camostat mesilate), which is being developed as a treatment for COVID-19.
Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes prnasia
June 02, 2021
Daewoong Pharmaceutical (CEO Sengho Jeon) announced that the results of an investigator-initiated clinical study on the effect of Enavogliflozin, originally developed as Type II Diabetes Treatment for humans, on treating canine diabetes were published ...
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test prnasia
May 28, 2021
Daewoong Pharmaceutical of South Korea has announced the promising clinical results of DWN12088, which is being developed as a first-in-class Prolyl-tRNA Synthetase(PRS) inhibitor for idiopathic pulmonary fibrosis (IPF) .
Daewoong showed improved performance both sales and earnings in Q1 prnasia
May 08, 2021
Daewoong Pharmaceutical(CEO Sengho Jeon) announced its management performance (based on consolidation) in Q1 of 2021. Its sales and operating profit were 269.6 billion and 26.6 billion KRW.
Avacta, Daewoong Expand Affimer Alliance contractpharma
July 31, 2020
To develop stem cell therapies for COVID-19 and future pandemic diseases.